Table 1.
Patient characteristics
| Characteristics | Clinical care pathway (n = 479) | Extended observation period (n = 474) | ||
|---|---|---|---|---|
| Frequency (%) | Missing values | Frequency (%) | Missing values | |
| Observation period | 876 patient‐years (median 2) | 5a | 2231 patient‐years (median 5) | 17b |
| Age (median, IQR) | 58.0 (46.1, 71.1) | 0 | 58.0 (46.1, 71.0) | 0 |
| Females | 242 (50.5) | 0 | 239 (50.4) | 0 |
| Duration of anticoagulation (mutually exclusive groups) | ||||
| 3 months | 75 (15.7) | 0 | 75 (15.8) | 0 |
| 6 months | 230 (48.0) | 0 | 228 (48.10) | 0 |
| 12 months | 95 (19.8) | 0 | 95 (20.1) | 0 |
| Indefinite | 79 (16.5) | 0 | 76 (16.0) | 0 |
| Provoking risk factors (mutually exclusive groups) | ||||
| Provoked by surgeryc | 95 (19.9) | 0 | 95 (20.0) | 0 |
| Non‐surgical transient risk factorc | 107 (22.3) | 0 | 106 (22.4) | 0 |
| Unprovoked VTEc | 265 (55.3) | 0 | 261 (55.1) | 0 |
| Active cancerc | 12 (2.5) | 0 | 12 (2.5) | 0 |
| Other risk factors | ||||
| Pregnancyd | 6 (1.3) | 0 | 6 (1.3) | 0 |
| Contraceptive use at the time of thrombosisd | 50 (10.4) | 6 | 50 (10.6) | 6 |
| Traveld | 34 (7.1) | 0 | 34 (7.2) | 0 |
| Immobilizationd | 40 (8.4) | 6 | 39 (8.2) | 6 |
| Inflammationd | 64 (13.4) | 7 | 63 (13.3) | 7 |
| Previous VTEd | 91 (19.0) | 0 | 90 (19.0) | 0 |
| Cardiovascular diseased | 115 (24.0) | 5 | 115 (24.3) | 5 |
| Heart failured | 6 (1.3) | 6 | 6 (1.3) | 6 |
| Known thrombophiliad | 19 (4.0) | 7 | 18 (3.8) | 7 |
| Venous insufficiencyd | 31 (6.5) | 8 | 31 (6.5) | 8 |
| Varicosisd | 22 (4.6) | 177 | 22 (4.6) | 173 |
| Residual thrombosisd , e | 144 (30.1) | 60 | 141 (29.8) | 58 |
| Smokingd | 107 (22.3) | 29 | 106 (22.4) | 26 |
| Family historyd | 140 (29.2) | 14 | 138 (29.1) | 14 |
| Risk factors not assessed at baseline | ||||
| Elevated D‐dimerd , f | 112 (23.4) | 122 | 112 (23.6) | 119 |
| Elevated CRPd , f | 109 (22.8) | 174 | 109 (23.0) | 171 |
| Elevated FVIIId& | 65 (13.6) | 157 | 65 (13.7) | 153 |
| Elevated Villalta scored , g , h | 78 (16.3) | 96 | 78 (16.5) | 94 |
CRP, C‐reactive protein; IQR, inter‐quartile range; VTE, venous thromboembolism.
a
Moved abroad.
b
Lost to follow‐up.
c
Mutually exclusive groups.
d
Patients can be subject to more than one risk factor.
e
One week before intended stop of OAC.
f
One month after stopping OAC.
g
At six months.
h
≥5 points & ≥213%; corresponding to the 80th percentile of the study population.